Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000–2013

Yonatan H. Grad, Simon R. Harris, Robert D. Kirkcaldy, Anna G. Green, Debora S. Marks, Stephen D. Bentley, David L. Trees, Marc LipsitchThe Journal of Infectious Diseases 2016 · DOI

TL;DR

This study uses genomic sequencing to track the evolution of antibiotic resistance in Neisseria gonorrhoeae in the US from 2000-2013. It reveals that while some resistance mechanisms are well-understood and could be targeted by rapid diagnostics, others remain elusive, highlighting the continued need for traditional susceptibility testing and urgent strategies to combat multidrug-resistant strains.

What Problem Does This Paper Address?

Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, is a major public health concern, particularly due to its increasing resistance to antibiotics. Treatment for gonorrhea is typically empirical, meaning doctors prescribe antibiotics based on the most likely effective drugs for the population, rather than testing each individual infection. This approach is becoming increasingly risky as resistance to key antibiotics like extended-spectrum cephalosporins (ESCs), macrolides (specifically azithromycin), and fluoroquinolones rises. The development of rapid, sequence-based diagnostic tests that can predict resistance based on genetic markers is a promising avenue. However, the effectiveness of such tests hinges on understanding the prevalence, genetic basis, and evolutionary dynamics of these resistance mechanisms. This paper aims to fill this knowledge gap by providing a comprehensive genomic and epidemiological analysis of resistance in N. gonorrhoeae over a 14-year period in the United States.

Methods

The researchers analyzed 1102 clinical isolates of N. gonorrhoeae collected between 2000 and 2013 through the Centers for Disease Control and Prevention's Gonococcal Isolate Surveillance Project (GISP).

  • Phenotypic Susceptibility Testing: Standard agar dilution methods were used to determine the minimum inhibitory concentrations (MICs) of key antibiotics, classifying isolates as resistant or susceptible.
  • Whole-Genome Sequencing: DNA from each isolate was sequenced using Illumina HiSeq.
  • Bioinformatic Analysis:
    • Read Mapping: Illumina sequencing reads were mapped to a reference genome (N. gonorrhoeae strain FA1090) using BWA MEM.
  • SNP Calling: Single-nucleotide polymorphisms (SNPs) were identified.
  • Assembly: Reads were assembled using Velvet and VelvetOptimiser.
  • Phylogenetic Analysis: A maximum likelihood whole-genome phylogeny was constructed based on SNPs to visualize the evolutionary relationships between isolates.
  • Population Structure Analysis: Bayesian analysis of population structure (BAPS) was used to identify distinct genetic clusters (clades) within the isolates.
  • NG-MAST and Recombination Analysis: These methods were employed to understand the genetic relatedness and potential for gene exchange between isolates.

The novelty lies in the large-scale, longitudinal genomic analysis combined with detailed phenotypic data, allowing for the tracking of resistance evolution and spread over more than a decade.

Datasets

The primary dataset consists of 1102 clinical isolates of Neisseria gonorrhoeae collected from 36 sexually transmitted disease (STD) clinics across the United States between 2000 and 2013, sourced from the Gonococcal Isolate Surveillance Project (GISP). This dataset is characterized by its longitudinal nature and the inclusion of both resistant and susceptible isolates, providing a rich resource for studying resistance dynamics.

Key Insights and Ideas

  • Clonal Expansion Drives ESC Resistance: The majority of resistance to extended-spectrum cephalosporins (ESCs) is driven by the expansion of specific genetic lineages (clades) that carry the mosaic penA XXXIV allele. This suggests that once a successful resistant lineage emerges, it can spread efficiently through clonal expansion.
  • Multiple Pathways for Azithromycin Resistance: Unlike ESC resistance, azithromycin resistance appears to arise through multiple genetic mechanisms, including mutations in 23S ribosomal RNA (rRNA) and interspecies mosaics in the mtr operon. The fact that a significant portion of azithromycin-resistant isolates have unexplained resistance mechanisms highlights the complexity and ongoing evolution of this resistance.
  • Quinolone Resistance is Highly Clonal and Predictable: Quinolone resistance is strongly associated with specific mutations in the gyrA and parC genes. The study found that these genetic markers are highly predictive of resistance, suggesting that rapid, genotype-based diagnostics could be effective for guiding quinolone therapy.
  • Potential for Fitness Costs Varies: While some resistance mechanisms, like those conferring quinolone resistance, appear to have minimal fitness costs (allowing for widespread clonal spread), others, like azithromycin resistance, seem to incur higher fitness costs, leading to less clonal expansion and more frequent reversion to susceptibility.
  • Multidrug Resistance is a Growing Threat: The identification of isolates resistant to multiple classes of antibiotics underscores the urgent need for new strategies to combat untreatable gonorrhea.

Key Results

  • ESC Resistance: Predominantly driven by the mosaic penA XXXIV allele, associated with 98% of cefixime-resistant and 91% of ceftriaxone-resistant isolates. This resistance is largely confined to two major clades.
  • Azithromycin Resistance: Associated with 23S rRNA mutations (C2611T and A2059G) and mtr operon mosaics. These mechanisms explain 64% of azithromycin-resistant isolates, with 36% having unexplained resistance. Azithromycin resistance shows less clonal expansion compared to ESC and quinolone resistance.
  • Quinolone Resistance: Emerged multiple times and is highly clonal, strongly correlated with gyrA and parC mutations. Haplotypes of these genes are highly predictive of resistance levels.
  • Multidrug Resistance: Five isolates exhibited resistance to ESCs and azithromycin, with four of these also showing resistance to quinolones.

Limitations and Future Work

  • Limitations:
    • The GISP isolates are primarily from men with gonococcal urethritis, potentially limiting their representativeness of infections at other mucosal sites.
  • The selection of isolates based on susceptibility profiles might introduce bias, as susceptible comparators were often chosen because they were resistant to other drugs.
  • Susceptibility testing has a margin of error, though the high predictive values of genetic markers suggest a limited impact.
  • Future Work:
    • The study emphasizes the need for continued phenotypic surveillance to identify and understand novel resistance mechanisms, particularly for ceftriaxone and azithromycin.
  • The amenability of quinolone and reduced cefixime resistance to sequence-based diagnostics is highlighted, suggesting further development in this area.
  • The identification of multidrug-resistant isolates necessitates the development of additional measures to combat untreatable gonorrhea, including novel diagnostic and therapeutic strategies.

Summary updated

Abstract

Quinolone-resistant N. gonorrhoeae and reduced cefixime susceptibility appear amenable to development of sequence-based diagnostic tests, whereas the undefined mechanisms of resistance to ceftriaxone and azithromycin underscore the importance of phenotypic surveillance. The identification of multidrug-resistant isolates highlights the need for additional measures to respond to the threat of untreatable gonorrhea.
BibTeX
@article{grad2016genomic,
  author = {Yonatan H. Grad and Simon R. Harris and Robert D. Kirkcaldy and Anna G. Green and Debora S. Marks and Stephen D. Bentley and David L. Trees and Marc Lipsitch},
  title = {{Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000–2013}},
  journal = {The Journal of Infectious Diseases},
  year = {2016},
  doi = {10.1093/infdis/jiw420},
}
Figure